Role of chemotherapy and novel biological agents in the treatment of elderly patients with colorectal cancer

World Journal of Gastroenterology

Volumn 14, Issue 12, 2008, Pages 1812-1822

  Rosati, Gerardo ^a   Bilancia, Domenico ^a  

^a SAN CARLO HOSPITAL   (Italy)

Author keywords

Bevacizumab; Cetuximab; Chemotherapy; Colorectal cancer; Elderly patients

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; INTERFERON; IRINOTECAN; LEVAMISOLE; METHOTREXATE; OXALIPLATIN; PLACEBO; RALTITREXED; UFT;

ABDOMINAL PAIN; ACUTE KIDNEY FAILURE; ADJUVANT THERAPY; AGED; AGING; ALOPECIA; ANEMIA; ANOREXIA; ASTHENIA; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER STAGING; CANCER SURVIVAL; CARDIOTOXICITY; CATHETER THROMBOSIS; CLINICAL TRIAL; COLON CANCER; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; COMORBIDITY; CONTINUOUS INFUSION; DEHYDRATION; DIARRHEA; DISEASE FREE SURVIVAL; DOSE KIDNEY FUNCTION RELATION; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; FATIGUE; FEBRILE NEUTROPENIA; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL TOXICITY; GERIATRIC ASSESSMENT; HAND FOOT SYNDROME; HUMAN; HYPERBILIRUBINEMIA; HYPERTENSION; INFECTION; KARNOFSKY PERFORMANCE STATUS; LARYNX SPASM; LETHARGY; LEUKOPENIA; LOW DRUG DOSE; LUNG EMBOLISM; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; QUALITY OF LIFE INDEX; RASH; REVIEW; SEPSIS; STOMATITIS; SURVIVAL RATE; THROMBOCYTOPENIA; VEIN THROMBOSIS; VOMITING;

EID: 42149124929     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.14.1812     Document Type: Review

References (66)

1. Jennens RR, Giles GG, Fox RM. Increasing underrepresentation of elderly patients with advanced colorectal or non-small-cell lung cancer in chemotherapy trials. Intern Med J 2006; 36: 216-220
2. Popescu RA, Norman A, Ross PJ, Parikh B, Cunningham D. Adjuvant or palliative chemotherapy for colorectal cancer in patients 70 years or older. J Clin Oncol 1999; 17: 2412-2418
3. Balducci L, Beghe C. The application of the principles of geriatrics to the management of the older person with cancer. Crit Rev Oncol Hematol 2000; 35: 147-154
4. Miller MD, Paradis CF, Houck PR, Mazumdar S, Stack JA, Rifai AH, Mulsant B, Reynolds CF 3rd. Rating chronic medical illness burden in geropsychiatric practice and research: application of the Cumulative Illness Rating Scale. Psychiatry Res 1992; 41: 237-248
5. Repetto L, Fratino L, Audisio RA, Venturino A, Gianni W, Vercelli M, Parodi S, Dal Lago D, Gioia F, Monfardini S, Aapro MS, Serraino D, Zagonel V. Comprehensive geriatric assessment adds information to Eastern Cooperative Oncology Group performance status in elderly cancer patients: an Italian Group for Geriatric Oncology Study. J Clin Oncol 2002; 20: 494-502
6. Kohne CH, Grothey A, Bokemeyer C, Bontke N, Aapro M. Chemotherapy in elderly patients with colorectal cancer. Ann Oncol 2001; 12: 435-442
7. Sargent DJ, Goldberg RM, Jacobson SD, Macdonald JS, Labianca R, Haller DG, Shepherd LE, Seitz JF, Francini G. A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med 2001; 345: 1091-1097
8. Twelves C, Wong A, Nowacki MP, Abt M, Burris H 3rd, Carrato A, Cassidy J, Cervantes A, Fagerberg J, Georgoulias V, Husseini F, Jodrell D, Koralewski P, Kroning H, Maroun J, Marschner N, McKendrick J, Pawlicki M, Rosso R, Schuller J, Seitz JF, Stabuc B, Tujakowski J, Van Hazel G, Zaluski J, Scheithauer W. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 2005; 352: 2696-2704
9. Diaz-Rubio E, Burris HA, Douillard JY Coxon FY, Maughan T, Berretto O, Schueller J, Husseini F, Marschner N, Scheithauer W. Safety of capecitabine (X) compared to fluorouracil/leucovorin (5-FU/LV) for the adjuvant treatment of elderly colon cancer patients (pts). Proceedings of the 40th Annual Meeting of American Society of Clinical Oncology; 2004 Jun 5-8; New Orleans, USA. Alexandria: American Society of Clinical Oncology, 2004: 304
10. Goldberg RM, Tabah-Fisch I, Bleiberg H, de Gramont A, Tournigand C, Andre T, Rothenberg ML, Green E, Sargent DJ. Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovonin administered bimonthly in elderly patients with colorectal cancer. J Clin Oncol 2006; 24: 4085-4091
11. Andre T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T, Topham C, Zaninelli M, Clingan P, Bridgewater J, Tabah-Fisch I, de Gramont A. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004; 350: 2343-2351
12. Diasio RB, Harris BE. Clinical pharmacology of 5-fluorouracil. Clin Pharmacokinet 1989; 16: 215-237
13. Milano G, Etienne MC, Cassuto-Viguier E, Thyss A, Santini J, Frenay M, Renee N, Schneider M, Demard F. Influence of sex and age on fluorouracil clearance. J Clin Oncol 1992; 10: 1171-1175
14. Beretta G, Bollina R, Cozzi C, Beretta GA, Morabito A & Members of the GOAL-Group of Oncomedical Associates in Lombardy. Should we consider the weekly chemotherapy with fluorouracil + racemic folinic acid a standard treatment for advanced/metastatic carcinoma of digestive tract in elderly patients? Proceedings of the 33rd Annual Meeting of American Society of Clinical Oncology; 1997 May 17-20; Denver, USA. Alexandria: American Society of Clinical Oncology, 1997: 259
15. Daniele B, Rosati G, Tambaro R, Ottaiano A, De Maio E, Pignata S, Iaffaioli RV, Rossi A, Manzione L, Gallo C, Perrone F. First-line chemotherapy with fluorouracil and folinic acid for advanced colorectal cancer in elderly patients: a phase II study. J Clin Gastroenterol 2003; 36: 228-233
16. Mattioli R, Lippe P, Recchia F, Massacesi C, Imperatori L, De Filippis S, Rosselli M, Gattafoni P, Casadei V, Consales D. Advanced colorectal cancer in elderly patients: tolerance and efficacy of leucovorin and fluorouracil bolus plus continuous infusion. Anticancer Res 2001; 21: 489-492
17. Folprecht G, Cunningham D, Ross P, Glimelius B, Di Costanzo F, Wils J, Scheithauer W, Rougier P, Aranda E, Hecker H, Kohne CH. Efficacy of 5-fluorouracil-based chemotherapy in elderly patients with metastatic colorectal cancer: a pooled analysis of clinical trials. Ann Oncol 2004; 15: 1330-1338
18. Cunningham D, Zalcberg JR Rath U, Oliver I, van Cutsem E, Svensson C, Seitz JF, Harper P, Kerr D, Perez-Manga G. Final results of a randomised trial comparing 'Tomudex' (raltitrexed) with 5-fluorouracil plus leucovorin in advanced colorectal cancer. "Tomudex" Colorectal Cancer Study Group. Ann Oncol 1996; 7: 961-965
19. Drug-company decision to end cancer trial. Lancet 1999; 354: 1045
20. Kohne CH, Thuss-Patience P, Friedrich M, Daniel PT, Kretzschmar A, Benter T, Bauer B, Dietz R, Dorken B. Raltitrexed (Tomudex): an alternative drug for patients with colorectal cancer and 5-fluorouracil associated cardiotoxicity. Br J Cancer 1998; 77: 973-977
21. Mel JR, Feliu J, Camps C, Escudero P, Aparicio J, Menendez D, Giron CG, Rodriguez MR, Grande C, Duque A, Garcia de Paredes M, Oncopaz G. Tomudex (Raltitrexed) in elderly patients with advanced colorectal cancer: an effective palliative treatment. Proceedings of the 36th Annual Meeting of American Society of Clinical Oncology; 2000 May 20-23; New Orleans, USA. Alexandria: American Society of Clinical Oncology, 2000: 257a
22. Facchini T, Genet D, Berdah JF, Nouyrigat P, Dutin JP, Laplaige P, Haguenauer D. Raltitrexed (Tomudex) has a manageable toxicity profile in elderly patients with metastatic colorectal cancer: Final analysis of a multicentre study. Proceedings of the 36th Annual Meeting of American Society of Clinical Oncology; 2000 May 20-23; New Orleans, USA. Alexandria: American Society of Clinical Oncology, 2000: 298a
23. Rustum YM. Mechanism-based improvement in the therapeutic selectivity of 5-FU prodrug alone and under conditions of metabolic modulation. Oncology 1997; 54 Suppl 1: 7-11
24. Hoff PM, Pazdur R, Benner SE, Canetta R. UFT and leucovorin: a review of its clinical development and therapeutic potential in the oral treatment of cancer. Anticancer Drugs 1998; 9: 479-490
25. Pazdur R, Douillard JY, Skillings JR, Eisenberg PD, Davidson N, Harper P, Vincent MD, Lembersky BC, Bermer SE. Multicenter ticenter phase III study of 5-fluorouracil (5-FU) or UFT™ in combination with leucovorin (LV) in patients with metastatic colorectal cancer. Proceedings of the 35th Annual Meeting of American Society of Clinical Oncology; 1999 May 15-18; Atlanta, USA. Alexandria: American Society of Clinical Oncology, 1999: 263a
26. Carmichael J, Popiela T, Radstone D, Falk S, Fey M, Oza A, Skovsgaard T, Martin C. Randomized comparative study of ORZEL (oral uraciL/tegafur (UFT)™) plus leucovorin (LV) versus parenteral 5-fluorouracil (5-FU plus LV) in patients with metastatic colorectal cancer. Proceedings of the 35th Annual Meeting of American Society of Clinical Oncology; 1999 May 15-18; Atlanta, USA. Alexandria: American Society of Clinical Oncology, 1999: 264a
27. Diaz-Rubio E, Sastre J, Abad A, Navarro M, Aranda E, Carrato A, Gallen M, Marcuello E, Rifa J, Massuti T, Cervantes A, Anton A, Fernandez Martos C. UFT plus or minus calcium folinate for metastatic colorectal cancer in older patients. Oncology (Williston Park) 1999; 13: 35-40
28. Feliu J, Gonzalez Baron M, Espinosa E, Garcia Giron C, de la Gandara I, Espinosa J, Colmenarejo A, Jalon JI, Fernandez Y, de Castro J. Uracil and tegafur modulated with leucovorin: an effective regimen with low toxicity for the treatment of colorectal carcinoma in the elderly. Oncopaz Cooperative Group. Cancer 1997; 79: 1884-1889
29. Popa EC, Luo W, Hochster H, Lyman B, Mulcahy M, Beatty P, Benson AB. A phase II study of orzel (UFT+leucovorin) in elderly (≥75 years old) patients with colorectal cancer: results of ECOG 1299. Proceedings of the 41st Annual Meeting of American Society of Clinical Oncology; 2005 May 13-17; Orlando, USA. Alexandria: American Society of Clinical Oncology, 2005: 273s
30. Twelves C, Glynne-Jones R, Cassidy J, Schuller J, Goggin T, Roos B, Banken L, Utoh M, Weidekamm E, Reigner B. Effect of hepatic dysfunction due to liver metastases on the pharmacokinetics of capecitabine and its metabolites. Clin Cancer Res 1999; 5: 1696-1702
31. Van Cutsem E, Findlay M, Osterwalder B, Kocha W, Dalley D, Pazdur R, Cassidy J, Dirix L, Twelves C, Allman D, Seitz JF, Scholmerich J, Burger HU, Verweij J. Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: results of a randomized phase II study. J Clin Oncol 2000; 18: 1337-1345
32. Hoff PM, Ansari R, Batist G, Cox J, Kocha W, Kuperminc M, Maroun J, Walde D, Weaver C, Harrison E, Burger HU, Osterwalder B, Wong AO, Wong R. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol 2001; 19: 2282-2292
33. Twelves C, Harper P, Van Cutsem E, Thibault A, Shelygin YA, Burger HU, Allman D, Osterwalder B. A phase III trial (SO14796) of Xeloda™ (capecitabine) in previously untreated advanced/metastatic colorectal cancer. Proceedings of the 35th Annual Meeting of American Society of Clinical Oncology; 1999 May 15-18; Atlanta, USA. Alexandria: American Society of Clinical Oncology, 1999: 263a
34. Cripps MC, Vincent M, Jonker D, Kerr I, Dingle B, Martin LA, Mathews J, Biagi J, Knight G, Lam W. Dose reduced first-line capecitabine monotherapy in older and less fit patients with advanced colorectal cancer. Proceedings of the 41st Annual Meeting of American Society of Clinical Oncology; 2005 May 13-17; Orlando, USA. Alexandria: American Society of Clinical Oncology, 2005: 265s
35. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, Jandik P, Iveson T, Carmichael J, Alakl M, Gruia G, Awad L, Rougier P. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000; 355: 1041-1047
36. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, Maroun JA, Ackland SP, Locker PK, Pirotta N, Elfring GL, Miller LL. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000; 343: 905-914
37. Pazdur R, Zinner R, Rothenberg M, Von Hoff DD, Hainsworth JD, Blanke CD, Cox JV, Elfring GL, Wolf DL, Mohrland JS, Schaaf LJ, Petit RG. Age as a risk factor in irinotecan (CPT-11) treatment of 5-FU-refractory colorectal cancer. Proceedings of the 33rd Annual Meeting of American Society of Clinical Oncology; 1997 May 17-20; Denver, USA. Alexandria: American Society of Clinical Oncology, 1997: 260a
38. Schaaf LJ, Ichhpurani N, Elfring GL, Wolf D, Rothenberg M, Von Hoff D. Influence of age on the pharmacokinetics of irinotecan (CPT-11) and its metabolites, SN-38 and SN-38 glucuronide (SN-38G), in patients with previously treated colorectal cancer. Proceedings of the 33rd Annual Meeting of American Society of Clinical Oncology; 1997 May 17-20; Denver, USA. Alexandria: American Society of Clinical Oncology, 1997: 202a
39. Stewart G, Chau I, Norman AR, Katopodis O, Topham C, Middleton G, Hill M, Ross P, Oates J, Cunningham D. Elderly patients with fluoropyrimidine-resistant advanced colorectal cancer (CRC) derive similar benefit without excessive toxicity when treated with irinotecan monotherapy. Proceedings of the 40th Annual Meeting of American Society of Clinical Oncology; 2004 June 5-8; New Orleans, USA. Alexandria: American Society of Clinical Oncology, 2004: 276
40. Rothenberg ML, Cox JV, DeVore RF, Hainsworth JD, Pazdur R, Rivkin SE, Macdonald JS, Geyer CE Jr, Sandbach J, Wolf DL, Mohrland JS, Elfring GL, Miller LL, Von Hoff DD. A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma. Cancer 1999; 85: 786-795
41. Rosati G, Cordio S. Single-agent irinotecan as second-line weekly chemotherapy in elderly patients with advanced colorectal cancer. Tumori 2006; 92: 290-294
42. Bollina R, Toniolo D, Belloni P, Cozzi C, Clerici M. Oxaliplatin and irinotecan: phase I/II study in 5FU refractory advanced colorectal cancer elderly patients, a second line treatment. Proceedings of the 37th Annual Meeting of American Society of Clinical Oncology; 2001 May 12-15; San Francisco, USA. Alexandria: American Society of Clinical Oncology, 2001: 407a
43. Sastre J, Marcuello E, Masutti B, Navarro M, Gil S, Anton A, Abad A, Aranda E, Maurel J, Valladares M, Maestu I, Carrato A, Vicent JM, Diaz-Rubio E. Irinotecan in combination with fluorouracil in a 48-hour continuous infusion as first-line chemotherapy for elderly patients with metastatic colorectal cancer: a Spanish Cooperative Group for the Treatment of Digestive Tumors study. J Clin Oncol 2005; 23: 3545-3551
44. Souglakos J, Pallis A, Kakolyris S, Mavroudis D, Androulakis N, Kouroussis C, Agelaki S, Xenidis N, Milaki G, Georgoulias V. Combination of irinotecan (CPT-11) plus 5-fluorouracil and leucovorin (FOLFIRI regimen) as first line treatment for elderly patients with metastatic colorectal cancer: a phase II trial. Oncology 2005; 69: 384-390
45. Folprecht G, Seymour MT, Saltz L, Douillard JY, Stephens RJ, Van Cutsem E, Rougier P, Maughan TS, Kohne CH. Irinotecan/5-FU/FA (I-FU) or 5-FU/FA (EU) first-line therapy in older and younger patients with metastatic colorectal cancer: Combined analysis of 2,691 patients in randomised controlled trials. Proceedings of the 43rd Annual Meeting of American Society of Clinical Oncology; 2007 June 1-5; Chicago, USA. Alexandria: American Society of Clinical Oncology, 2007: 181s
46. Botto HG, Botto ME. Combination of irinotecan and 5-fluorouracil, leucovorin in first and second line treatment in elderly patients with metastatic colo-rectal cancer. Proceedings of the 41st Annual Meeting of American Society of clinical Oncology; 2005 May 13-17; Orlando, USA. Alexandria: American Society of Clinical Oncology, 2005: 306s
47. Fiorentini G, Dentico P, Cantore M, Rossi S, Pacetti P, Bernardeschi P, Della Seta R, Tumolo S, de Giorgi U. Capecitabine plus irinotecan as second-line treatment (XELIRI) for metastatic colorectal cancer in elderly patients: Feasibility and safety results from a phase II study. Proceedings of the 41st Annual Meeting of American Society of Clinical Oncology; 2005 May 13-17; Orlando, USA. Alexandria: American Society of Clinical Oncology, 2005: 289s
48. Raymond E, Faivre S, Woynarowski JM, Chaney SG. Oxaliplatin: mechanism of action and antineoplastic activity. Semin Oncol 1998; 25: 4-12
49. de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freyer G, Papamichael D, Le Bail N, Louvet C, Hendler D, de Braud F, Wilson C, Morvan F, Bonetti A. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18: 2938-2947
50. Berretta A, Buonadonna A, Rupolo M, Frustaci S, Bearz A, Sorio R, Freschi A, Scalone S, Michieli M, Spina M, Tirelli U, Colussi AM, Cartei G. Comparison between elderly and non-elderly patients of efficacy and tolerability of FOLFOX2 schedule in advanced colorectal cancer. Proceedings of the 37th Annual Meeting of American Society of Clinical Oncology; 2001 May 12-15; San Francisco, USA. Alexandria: American Society of Clinical Oncology, 2001: 111b
51. Comella P, Gambardella A, Farris A, Maiorino L, Natale D, Massidda B, Casaretti R, Tafuto S, Lorusso V, Leo S. A tailored regimen including capecitabine and oxaliplatin for treating elderly patients with metastatic colorectal carcinoma Southern Italy Cooperative Oncology Group trial 0108. Crit Rev Oncol Hematol 2005; 53: 133-139
52. Twelves CJ, Butts CA, Cassidy J, Conroy T, Braud F, Diaz-Rubio E, Tabernero JM, Schoffski P, Figer A, Brunet R, Grossmann J, Sobrero AF, Van Cutsem EJ. Capecitabine/oxaliplatin, a safe and active first-line regimen for older patients with metastatic colorectal cancer: post hoc analysis of a large phase II study. Clin Colorectal Cancer 2005; 5: 101-107
53. Feliu J, Salud A, Escudero P, Lopez-Gomez L, Bolanos M, Galan A, Vicent JM, Yubero A, Losa F, De Castro J, de Mon MA, Casado E, Gonzalez-Baron M. XELOX (capecitabine plus oxaliplatin) as first-line treatment for elderly patients over 70 years of age with advanced colorectal cancer. Br J Cancer 2006; 94: 969-975
54. Comandone A, Pochettino P, Bergnolo P, Boglione A, Dal Canton O, Chiado Cutin S, Garetto F, Biscardi M, Oliva C. Capecitabine and oxaliplatin: A phase II study with a new schedule of administration in elderly patients with advanced colorectal cancer. Proceedings of the 41st Annual Meeting of American Society of Clinical Oncology; 2005 May 13-17; Orlando, USA. Alexandria: American Society of Clinical Oncology, 2005: 291s
55. Rosati G, Cordio S, Tucci A, Blanco G, Bordonaro R, Reggiardo G, Manzione L. Phase II trial of oxaliplatin and tegafur/uracil and oral folinic acid for advanced or metastatic colorectal cancer in elderly patients. Oncology 2005; 69: 122-129
56. Mattioli R, Massacesi C, Recchia F, Marcucci F, Cappelletti C, Imperatori L, Pilone A, Rocchi M, Cesta A, Laici G, Bonsignori M, Lippe P. High activity and reduced neurotoxicity of bi-fractionated oxaliplatin plus 5-fluorouracil/leucovorin for elderly patients with advanced colorectal cancer. Ann Oncol 2005; 16: 1147-1151
57. Kim JH, Oh DY, Kim YJ, Han SW, Choi IS, Kim DW, Im SA, Kim TY, Lee JS, Heo DS, Bang YJ, Kim NK. Reduced dose intensity FOLFOX-4 as first line palliative chemotherapy in elderly patients with advanced colorectal cancer. J Korean Med Sci 2005; 20: 806-810
58. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I, Van Cutsem E. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351: 337-345
59. Tabernero JM, Van Cutsem E, Sastre J, Cervantes A, Van Laethem JL, Humblet Y, Soulié P, Corretgé S, Mueser M, De Gramont A. An international phase II study of cetuximab in combination with oxaliplatin/5-fluorouracil (5-FU)/folinic acid (FA) (FOLFOX-4) in the first-line treatment of patients with metastatic colorectal cancer (CRC) expressing Epidermal Growth Factor Receptor (EGFR). Preliminary results. Proceedings of the 40th Annual Meeting of American Society of Clinical Oncology; 2004 June 5-8; New Orleans, USA. Alexandria: American Society of Clinical Oncology, 2004: 248
60. Van Cutsem E, Nowacki M, Lang I, Cascinu S, Shchepotin I, Maurel J, Rougier P, Cunningham D, Nippgen J, Kohne C. Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): The CRYSTAL trial. Proceedings of the 43rd Annual Meeting of American Society of Clinical Oncology; 2007 June 1-5; Chicago, USA. Alexandria: American Society of Clinical Oncology, 2007: 164s
61. Sastre J, Aranda E, Grávalos C, Massuti B, Vega-Villegas ME, Soler G, Carrato A, Abad A, Gomez A, Diaz-Rubio E. Single-agent cetuximab as first-line treatment for elderly patients with advanced colorectal cancer. Preliminary results of a TTD phase II study. Proceedings of the 31st ESMO Congress; 2006 September 29-October 3; Istanbul, Turkey. Oxford: Oxford University Press, 2006: 114
62. Presta LG, Chen H, O'Connor SJ, Chisholm V, Meng YG, Krummen L, Winkler M, Ferrara N. Humanization of an antivascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997; 57: 4593-4599
63. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-2342
64. Knight RD, Miller LL, Pirotta N, Elfring GL, Locker PK, Saltz LB. First-line irinotecan (C), fluorouracil (F), leucovorin (L) especially improves survival (OS) in metastatic colorectal cancer (MCRC) patients (PT) with favourable prognostic indicators. Proceedings of the 36th Annual Meeting of American Society of Clinical Oncology; 2000 May 20-23; New Orleans, USA. Alexandria: American Society of Clinical Oncology, 2000: 255a
65. Kabbinavar FF, Schulz J, McCleod M, Patel T, Hamm JT, Hecht JR, Mass R, Perrou B, Nelson B, Novotny WF. Addition of bevacizumab to bolus fluorouracil and leucovorin in firstline metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol 2005; 23: 3697-3705
66. Rosati G, Cordio S, Bordonaro R, Gebbia V, Rinaldi A, Giannitto G, Borsellino N, Reggiardo G. Capecitabine in combination with oxaliplatin or with irinotecan in elderly patients with advanced colorectal cancer: Preliminary results of a randomized phase II study. Proceedings of the World Congress on Gastrointestinal Cancer; 2007 June 28-July 1; Barcelona, Spain. Oxford: Oxford University Press, 2007: 28-29